Abstract
Abstract only
- Title
- A Randomized, Double-blind, Phase 3 Study of Vorasidenib Versus Placebo in Patients with Mutant IDH1/2 Diffuse Glioma (INDIGO): Analysis of Health-related Quality of Life, Neurocognition and Seizures (PL5.003)
- Creators
- Macarena De La Fuente - University of MiamiKatherine Peters - Duke Medical CenterIngo Mellinghoff - Memorial Sloan Kettering Cancer CenterMartin Van Den Bent - Erasmus MCDeborah Blumenthal - Tel Aviv UniversityMehdi Touat - Assistance Publique – Hôpitaux de ParisJennifer Clarke - University of California, San FranciscoJoe Mendez - Huntsman Cancer InstituteShlomit Yust-Katz - Rabin Medical CenterWarren Mason - Toronto General HospitalFrancois Ducray - Hôpital Pierre WertheimerYoshie Umemura - University of Michigan–Ann ArborBurt Nabors - University of Alabama at BirminghamMatthias Holdhoff - Sidney Kimmel Comprehensive Cancer CenterAndreas Hottinger - University Hospital of LausanneYoshiki Arakawa - Kyoto UniversityJuan Sepúlveda - Hospital Universitario 12 De OctubreWolfgang Wick - University Hospital HeidelbergRiccardo Soffietti - University of TurinJames Perry - Sunnybrook Health Science CentrePierre Giglio - The Ohio State University Wexner Medical CenterElizabeth Maher - The University of Texas Southwestern Medical CenterAndrew Bottomley - Bottomley ConsultantsDan Zhao - Servier PharmaceuticalsShuchi Pandya - ServierIslam Hassan - ServierLori Steelman - ServierPatrick Wen - Dana–Farber Cancer InstituteTimothy Cloughesy - University of California, Los Angeles
- Publication Details
- Neurology, Vol.102(17_supplement_1)
- Academic Unit
- UMMG Dept of Neurology - Neuro-Oncology Div; Miller School of Medicine; UMMG Department of Neurology
- Language
- English
- Resource Type
- Journal article
- Record Identifier
- 991032064108102976